title: Exciting Therapies Ahead in Prostate Cancer.
abstract: Robust drug-development programs targeting the second most common male cancer (after skin cancer) will help increase U.S. market sales to $3.7 billion by 2023.
authors.forename: Kunj
authors.initials: K
authors.lastname: Gohil